10-Q: AbCellera Biologics Inc. Reports Third Quarter 2024 Results, Revenue Declines Amidst Increased R&D Spending

AbCellera Biologics Inc. reported a net loss of $51.1 million for the third quarter of 2024, with revenue decreasing slightly and operating expenses increasing significantly due to impairment charges.

Summary

• AbCellera Biologics Inc. reported a net loss of $51.1 million for the third quarter of 2024, compared to a net loss of $28.6 million in the same period of 2023.
• Total revenue for the quarter was $6.5 million, a slight decrease from $6.6 million in the third quarter of 2023.
• Operating expenses increased to $100.2 million, up from $61.5 million in the prior year's quarter, primarily due to a $32 million impairment charge related to IPR&D from the Trianni acquisition.
• Research and development expenses increased to $41 million, up from $37.9 million in the third quarter of 2023.
• The company's cash, cash equivalents, and marketable securities totaled $643.1 million as of September 30, 2024, down from $760.6 million at the end of 2023.
• The company has advanced a cumulative total of 14 molecules into the clinic, with 95 partner-initiated programs started with downstream participation.
• The company has received government contributions of $149.9 million, with $52.1 million non-repayable, $14.3 million conditionally repayable, and $32.6 million repayable.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive developments in the pipeline and partnerships, but the significant increase in net loss and operating expenses, along with a decrease in cash reserves, creates a negative sentiment. The impairment charges and the slight decrease in revenue also contribute to the negative outlook.

Positives

• The company has advanced a cumulative total of 14 molecules into the clinic, indicating progress in its drug discovery efforts.
• The company has started 95 partner-initiated programs with downstream participation, suggesting a strong pipeline for future revenue.
• The company recognized a $16.5 million gain on the disposal of a non-marketable security, contributing to other income.
• The company has secured significant government contributions, providing non-dilutive funding for research and development.

Negatives

• The company's net loss increased significantly to $51.1 million in Q3 2024, compared to $28.6 million in Q3 2023.
• Total revenue decreased slightly to $6.5 million in Q3 2024 from $6.6 million in Q3 2023.
• Operating expenses increased substantially to $100.2 million in Q3 2024, driven by a $32 million impairment charge.
• The company's cash, cash equivalents, and marketable securities decreased by $117.4 million since the end of 2023.
• The company recorded a full impairment charge of $32 million associated with the IPR&D acquired through the 2020 acquisition of Trianni.
• The company recorded a full impairment charge of $32 million associated with the IPR&D acquired through the 2021 acquisition of TetraGenetics.

Risks

• The company's future profitability is uncertain, and it may continue to incur significant losses.
• The company's revenue is subject to fluctuations and depends on the success of its partners' development and commercialization efforts.
• The company's reliance on a limited number of partners for revenue poses a risk to its financial stability.
• The company's ability to manage its growth and maintain its competitive position is subject to various challenges.
• The company's investments in research and development may not yield the expected returns.
• The company is subject to risks related to intellectual property protection and potential litigation.
• The company's operations are subject to government regulations and compliance requirements.
• The company's reliance on third-party suppliers and manufacturers poses a risk to its supply chain.
• The company's business is subject to risks related to foreign currency exchange rates and international operations.
• The company's business is subject to risks related to cyberattacks and data breaches.

Future Outlook

Based on the current business plan, the company believes that its available liquidity will be sufficient to meet its working capital and capital expenditure needs for at least the next 36 months, and does not anticipate the need for additional external funding.

Management Comments

• The company is focused on the development of antibody-based drugs and is committed to improving discovery and development.
• The company aims to build a competitive advantage in bringing antibody therapeutics from target into clinical testing.
• The company thinks deeply about capital allocation and strives to maximize long-term value while mitigating the risks that are inherent in drug development and in scaling a company.
• The company is advancing a pipeline of programs and strategically partnering with groups with novel science or innovative technology.

Industry Context

The report highlights the competitive nature of the life sciences and biotechnology platform technology market, with AbCellera facing competition from various companies offering similar technologies and services. The company's performance is also influenced by the overall health of the biotechnology industry and the research and development spending of pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• The company's reliance on milestone payments and royalties is typical in the biotechnology industry, where revenue is often tied to the success of drug development programs.
• The company's investment in research and development is consistent with industry trends, as companies in this sector need to continuously innovate to maintain a competitive edge.
• The company's partnerships with pharmaceutical and biotechnology companies are a common strategy for drug discovery and development companies.
• The company's focus on antibody-based drugs aligns with the growing interest in biologics as a therapeutic modality.
• The company's use of advanced technologies, such as single-cell screening and AI, is in line with the industry's push towards more efficient and effective drug discovery methods.
• The company's financial results are impacted by the inherent risks and uncertainties of drug development, which is a common challenge for companies in this sector.
• The company's impairment charges related to IPR&D are not uncommon in the biotechnology industry, where programs may be discontinued due to prioritization or lack of success.

Legal Proceedings

• The company is involved in patent infringement litigation against Bruker Cellular Analysis, with a jury trial scheduled for January 2026.
• The company is also involved in a civil litigation with the Estate of John Schrader, seeking dismissal of certain company affiliates from the matter.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves.
• Employees may be affected by the company's restructuring and reorganization activities.
• Customers and partners may be impacted by the company's ability to deliver on its commitments.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• The company will continue to invest in research and development activities to improve its antibody discovery and development engine.
• The company will pursue internal and co-development programs in preclinical and eventually clinical development.
• The company will market and sell its solutions to existing and new strategic partners.
• The company will expand and enhance operations to deliver programs, including investments in manufacturing.
• The company will continue to establish, protect and defend its intellectual property and patent portfolio.

Key Dates

Keywords

antibody discovery, biologics, drug development, research and development, licensing, milestone payments, clinical trials, intellectual property, government funding, financial results